메뉴 건너뛰기




Volumn 5, Issue 2, 2012, Pages 241-247

Healing the diabetic heart: Modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs)

Author keywords

Cardiometabolic syndrome; Diabetes mellitus; Herbal and traditional natural medicines; Peroxisome proliferatoractivated receptor

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; ALOGLIPTIN; CARBACYCLIN; FARGLITAZAR; FENOFIBRATE; FENOPROFEN; FLUFENAMIC ACID; GEMCABENE; GEMFIBROZIL; GW 2331; GW 2433; IBUPROFEN; INDOMETACIN; L 796449; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PIRINIXIC ACID; PLASTICIZER; REGLITAZAR; ROSIGLITAZONE; TOMELUKAST; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID;

EID: 84861759663     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020241     Document Type: Review
Times cited : (7)

References (73)
  • 1
    • 56949101509 scopus 로고    scopus 로고
    • Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects
    • Dervaux, N.; Wubuli, M.; Megnien, J.L.; Chironi, G.; Simon, A. Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects. Atherosclerosis, 2008, 201, 413-417.
    • (2008) Atherosclerosis , vol.201 , pp. 413-417
    • Dervaux, N.1    Wubuli, M.2    Megnien, J.L.3    Chironi, G.4    Simon, A.5
  • 2
    • 79960853510 scopus 로고    scopus 로고
    • Vascular biology of metabolic syndrome
    • Vykoukal, D.; Davies, M.G. Vascular biology of metabolic syndrome. J. Vasc. Surg., 2011, 54(3), 819-831.
    • (2011) J. Vasc. Surg , vol.54 , Issue.3 , pp. 819-831
    • Vykoukal, D.1    Davies, M.G.2
  • 4
    • 67651121708 scopus 로고    scopus 로고
    • The role of PPARs in modulating cardiac metabolism in diabetes
    • Holness, M.J.; Samsuddin, S.; Sugden, M.C. The role of PPARs in modulating cardiac metabolism in diabetes. Pharmacol. Res., 2009, 60, 185-194.
    • (2009) Pharmacol. Res , vol.60 , pp. 185-194
    • Holness, M.J.1    Samsuddin, S.2    Sugden, M.C.3
  • 7
    • 84874304580 scopus 로고    scopus 로고
    • Exploring the Complexity of Cardiometabolic Risk in Women
    • [Epub ahead of print]
    • Robins, J.L.; McCain, N.L.; Elswick, R.K. Jr. Exploring the Complexity of Cardiometabolic Risk in Women. Biol. Res. Nurs., 2011, [Epub ahead of print].
    • (2011) Biol. Res. Nurs
    • Robins, J.L.1    McCain, N.L.2    Elswick Jr., R.K.3
  • 8
    • 33846365989 scopus 로고    scopus 로고
    • Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies
    • Gami, A.S.; Witt, B.J.; Howard, D.E.; Erwin, P.J.; Gami, L.A.; Somers, V.K.; Montori, V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 2007, 49, 403-414.
    • (2007) J. Am. Coll. Cardiol , vol.49 , pp. 403-414
    • Gami, A.S.1    Witt, B.J.2    Howard, D.E.3    Erwin, P.J.4    Gami, L.A.5    Somers, V.K.6    Montori, V.M.7
  • 9
    • 79958065049 scopus 로고    scopus 로고
    • Identification and management of cardiometabolic risk in Canada: A position paper by the cardiometabolic risk working group (executive summary)
    • Cardiometabolic Risk Working Group: Executive Committee
    • Cardiometabolic Risk Working Group: Executive Committee.; Leiter, L.A.; Fitchett, D.H.; Gilbert, R.E.; Gupta, M.; Mancini, G.B.; McFarlane P.A.; Ross, R.; Teoh, H.; Verma, S. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can. J. Cardiol., 2011, 27, 124-131.
    • (2011) Can. J. Cardiol , vol.27 , pp. 124-131
    • Leiter, L.A.1    Fitchett, D.H.2    Gilbert, R.E.3    Gupta, M.4    Mancini, G.B.5    McFarlane, P.A.6    Ross, R.7    Teoh, H.8    Verma, S.9
  • 10
    • 52949130244 scopus 로고    scopus 로고
    • The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology
    • Després, J.P.; Cartier, A.; Côté, M.; Arsenault, B.J. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med., 2008, 40, 514-523.
    • (2008) Ann Med , vol.40 , pp. 514-523
    • Després, J.P.1    Cartier, A.2    Côté, M.3    Arsenault, B.J.4
  • 11
    • 72449152949 scopus 로고    scopus 로고
    • Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: Results from large scale efficacy trials
    • Horton, E.S. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring), 2009, 17(Suppl. 3), S43-S48.
    • (2009) Obesity (Silver Spring) , vol.17 , Issue.SUPPL. 3
    • Horton, E.S.1
  • 12
    • 47349107995 scopus 로고    scopus 로고
    • Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders
    • Cho, M.C.; Lee, K.; Paik, S.G.; Yoon, D.Y. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res., 2008, 2008, 679137.
    • (2008) PPAR Res , vol.2008 , pp. 679137
    • Cho, M.C.1    Lee, K.2    Paik, S.G.3    Yoon, D.Y.4
  • 13
    • 67651154149 scopus 로고    scopus 로고
    • The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome
    • Huang, T.H.; Teoh, A.W.; Lin, B.L.; Lin, D.S.; Roufogalis, B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol. Res., 2009, 60, 195-206.
    • (2009) Pharmacol. Res , vol.60 , pp. 195-206
    • Huang, T.H.1    Teoh, A.W.2    Lin, B.L.3    Lin, D.S.4    Roufogalis, B.5
  • 14
    • 23944443718 scopus 로고    scopus 로고
    • Regulation of gene transcription by botanicals: Novel regulatory mechanisms
    • Shay, N.F.; Banz, W.J. Regulation of gene transcription by botanicals: novel regulatory mechanisms. Annu. Rev. Nutr., 2005, 25, 297-315.
    • (2005) Annu. Rev. Nutr , vol.25 , pp. 297-315
    • Shay, N.F.1    Banz, W.J.2
  • 15
    • 47949094965 scopus 로고    scopus 로고
    • Integration of metabolism and inflammation by lipid-activated nuclear receptors
    • Bensinger, S.J.; Tontonoz, P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature, 2008, 454, 470-477.
    • (2008) Nature , vol.454 , pp. 470-477
    • Bensinger, S.J.1    Tontonoz, P.2
  • 16
    • 0033793133 scopus 로고    scopus 로고
    • Peroxisome proliferatoractivated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
    • Chinetti, G.; Fruchart, J.C.; Staels, B. Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 2000, 49, 497-505.
    • (2000) Inflamm. Res , vol.49 , pp. 497-505
    • Chinetti, G.1    Fruchart, J.C.2    Staels, B.3
  • 17
    • 11144310564 scopus 로고    scopus 로고
    • An overview on biological mechanisms of PPARs
    • Kota, B.P.; Huang, T.H.; Roufogalis, B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res., 2005, 51, 85-94.
    • (2005) Pharmacol. Res , vol.51 , pp. 85-94
    • Kota, B.P.1    Huang, T.H.2    Roufogalis, B.D.3
  • 19
    • 0034668205 scopus 로고    scopus 로고
    • Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
    • Neve, B.P.; Fruchart, J.C.; Staels, B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol., 2000. 60, 1245-1250.
    • (2000) Biochem. Pharmacol , vol.60 , pp. 1245-1250
    • Neve, B.P.1    Fruchart, J.C.2    Staels, B.3
  • 20
    • 42749100646 scopus 로고    scopus 로고
    • Selective Modulators of PPARgamma Activity: Molecular Aspects Related to Obesity and Side-Effects
    • Zhang F, Lavan BE, Gregoire FM. Selective Modulators of PPARgamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res., 2007, 32696.
    • (2007) PPAR Res , pp. 32696
    • Zhang, F.1    Lavan, B.E.2    Gregoire, F.M.3
  • 21
    • 0030877565 scopus 로고    scopus 로고
    • Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and-2 isoforms and influence of insulin
    • Werman, A.; Hollenberg, A.; Solanes, G.; Bjorbaek, C.; Vidal-Puig, A.J.; Flier, J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and-2 isoforms and influence of insulin. J. Biol. Chem., 1997, 272, 20230-20235.
    • (1997) J. Biol. Chem , vol.272 , pp. 20230-20235
    • Werman, A.1    Hollenberg, A.2    Solanes, G.3    Bjorbaek, C.4    Vidal-Puig, A.J.5    Flier, J.S.6
  • 22
    • 0036183630 scopus 로고    scopus 로고
    • The mechanisms of action of PPARs
    • Berger, J.; Moller, D.E. The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
    • (2002) Annu. Rev. Med , vol.53 , pp. 409-435
    • Berger, J.1    Moller, D.E.2
  • 23
    • 77958060003 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease
    • Azhar, S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol., 2010, 6, 657-691.
    • (2010) Future Cardiol , vol.6 , pp. 657-691
    • Azhar, S.1
  • 27
    • 34648832073 scopus 로고    scopus 로고
    • Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials
    • Lago, R.M.; Singh, P.P.; Nesto, R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet, 2007, 370, 1129-1136.
    • (2007) Lancet , vol.370 , pp. 1129-1136
    • Lago, R.M.1    Singh, P.P.2    Nesto, R.W.3
  • 28
    • 67149146438 scopus 로고    scopus 로고
    • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
    • RECORD Study Team
    • Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Curtis, P.S.; Gomis, R.; Hanefeld, M.; Jones, N.P.; Komajda, M.; McMurray, J.J.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 2009, 373, 2125-2135.
    • (2009) Lancet , vol.373 , pp. 2125-2135
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3    Curtis, P.S.4    Gomis, R.5    Hanefeld, M.6    Jones, N.P.7    Komajda, M.8    McMurray, J.J.9
  • 29
    • 79953203593 scopus 로고    scopus 로고
    • Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies
    • Loke, Y.K.; Kwok, C.S.; Singh, S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ, 2011, 342, d1309.
    • (2011) BMJ , vol.342
    • Loke, Y.K.1    Kwok, C.S.2    Singh, S.3
  • 30
    • 77649144555 scopus 로고    scopus 로고
    • Pioglitazone: Side effect and safety profile
    • Shah, P.; Mudaliar, S. Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf., 2010, 9, 347-354
    • (2010) Expert Opin. Drug Saf , vol.9 , pp. 347-354
    • Shah, P.1    Mudaliar, S.2
  • 31
    • 77956335013 scopus 로고    scopus 로고
    • Potential remains for PPAR-targeted drugs
    • Jones, D. Potential remains for PPAR-targeted drugs. Nat. Rev. Drug Discov., 2010, 668-669.
    • (2010) Nat. Rev. Drug Discov , pp. 668-669
    • Jones, D.1
  • 32
    • 77954667427 scopus 로고    scopus 로고
    • Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: Pioglitazone versus rosiglitazone
    • Simó, R.; Rodriguez, A.; Caveda, E. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr. Drug Saf., 2010, 5, 234-244.
    • (2010) Curr. Drug Saf , vol.5 , pp. 234-244
    • Simó, R.1    Rodriguez, A.2    Caveda, E.3
  • 33
    • 34548590934 scopus 로고    scopus 로고
    • Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
    • Lincoff, A.M.; Wolski, K.; Nicholls, S.J.; Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA, 2007, 298, 1180-1188.
    • (2007) JAMA , vol.298 , pp. 1180-1188
    • Lincoff, A.M.1    Wolski, K.2    Nicholls, S.J.3    Nissen, S.E.4
  • 35
    • 79952062014 scopus 로고    scopus 로고
    • Pioglitazone and alogliptin combination therapy in type 2 diabetes: A pathophysiologically sound treatment
    • Triplitt, C.; Cersosimo, E.; DeFronzo, R.A. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc. Health Risk Manag., 2010, 6, 671-690.
    • (2010) Vasc. Health Risk Manag , vol.6 , pp. 671-690
    • Triplitt, C.1    Cersosimo, E.2    DeFronzo, R.A.3
  • 37
    • 67649852314 scopus 로고    scopus 로고
    • PPAR-alpha and PPAR-gamma agonists for type 2 diabetes
    • Charbonnel, B. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. Lancet, 2009, 374, 96-98.
    • (2009) Lancet , vol.374 , pp. 96-98
    • Charbonnel, B.1
  • 38
    • 0036040929 scopus 로고    scopus 로고
    • Effects of fibrates on serummetabolic parameters
    • Elisaf, M. Effects of fibrates on serummetabolic parameters. Curr. Med. Res. Opin., 2002, 18, 269-276.
    • (2002) Curr. Med. Res. Opin , vol.18 , pp. 269-276
    • Elisaf, M.1
  • 40
    • 50649089597 scopus 로고    scopus 로고
    • Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
    • Staels, B.; Maes.; M.; Zambon, A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5, 542-553.
    • (2008) Nat. Clin. Pract. Cardiovasc. Med , vol.5 , pp. 542-553
    • Staels, B.1    Maes, M.2    Zambon, A.3
  • 42
    • 47249146946 scopus 로고    scopus 로고
    • PPAR modulators and PPAR pan agonists for metabolic diseases: The next generation of drugs targeting peroxisome proliferator-activated receptors?
    • Feldman, P.L.; Lambert, M.H.; Henke, B.R. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr. Top. Med. Chem., 2008. 8, 728-749.
    • (2008) Curr. Top. Med. Chem , vol.8 , pp. 728-749
    • Feldman, P.L.1    Lambert, M.H.2    Henke, B.R.3
  • 43
    • 35448951406 scopus 로고    scopus 로고
    • Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist
    • Waites, C.R.; Dominick, M.A.; Sanderson, T.P.; Schilling, B.E. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. Toxicol. Sci., 2007, 100, 248-258.
    • (2007) Toxicol. Sci , vol.100 , pp. 248-258
    • Waites, C.R.1    Dominick, M.A.2    Sanderson, T.P.3    Schilling, B.E.4
  • 44
    • 26844431513 scopus 로고    scopus 로고
    • Dual and pan-peroxisome proliferatoractivated receptors (PPAR) co-agonism: The bezafibrate lessons
    • Tenenbaum, A.; Motro, M.; Fisman, E.Z. Dual and pan-peroxisome proliferatoractivated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol., 2005, 4, 14.
    • (2005) Cardiovasc. Diabetol , vol.4 , pp. 14
    • Tenenbaum, A.1    Motro, M.2    Fisman, E.Z.3
  • 46
    • 79955586140 scopus 로고    scopus 로고
    • Dual acting and pan-PPAR activators as potential anti-diabetic therapies
    • Heald, M.; Cawthorne, M.A. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. Handb. Exp. Pharmacol., 2011, 203, 35-51.
    • (2011) Handb. Exp. Pharmacol , vol.203 , pp. 35-51
    • Heald, M.1    Cawthorne, M.A.2
  • 47
    • 60849100836 scopus 로고    scopus 로고
    • The development of INT131 as a selective PPARc modulator (SPPARM): Approach to a safer insulin sensitizer
    • Higgins, L.S.; Mantzoros, C.M. The development of INT131 as a selective PPARc modulator (SPPARM): approach to a safer insulin sensitizer. PPAR Res., 2008, 2008, 936906.
    • (2008) PPAR Res , vol.2008 , pp. 936906
    • Higgins, L.S.1    Mantzoros, C.M.2
  • 50
    • 0036090467 scopus 로고    scopus 로고
    • Divergent effects of selective peroxisome proliferator-activated receptorc-2 ligands on adipocyte versus osteoblast differentiation
    • Lecka-Czernik, B.; Moerman, E.J.; Grant, D.F.; Lehmann, J.M.; Manolagas, S.C.; Jilka, R.L. Divergent effects of selective peroxisome proliferator-activated receptorc-2 ligands on adipocyte versus osteoblast differentiation. Endocrinology, 2002, 143, 2376-2384.
    • (2002) Endocrinology , vol.143 , pp. 2376-2384
    • Lecka-Czernik, B.1    Moerman, E.J.2    Grant, D.F.3    Lehmann, J.M.4    Manolagas, S.C.5    Jilka, R.L.6
  • 51
    • 74049159051 scopus 로고    scopus 로고
    • Selective peroxisome proliferatoractivated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation
    • Higgins, L.S.; Depaoli, A.M. Selective peroxisome proliferatoractivated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am. J. Clin. Nutr., 2010, 91, 267S-272S.
    • (2010) Am. J. Clin. Nutr , vol.91
    • Higgins, L.S.1    Depaoli, A.M.2
  • 52
    • 33750580948 scopus 로고    scopus 로고
    • Halofenate is a selective peroxisome proliferatoractivated receptor gamma modulator with antidiabetic activity
    • Allen, T.; Zhang, F.; Moodie, S.A.; Clemens, L.E.; Smith, A.; Gregoire, F. Halofenate is a selective peroxisome proliferatoractivated receptor gamma modulator with antidiabetic activity. Diabetes, 2006, 55, 2523-2533.
    • (2006) Diabetes , vol.55 , pp. 2523-2533
    • Allen, T.1    Zhang, F.2    Moodie, S.A.3    Clemens, L.E.4    Smith, A.5    Gregoire, F.6
  • 53
    • 53149121998 scopus 로고    scopus 로고
    • Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist
    • Clarke, H.J.; Gregoire, F.; Ma, F.; Martin, R.; Zhao, S.; Lavan, B.E. Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist. PPAR Res., 2008, 2008, 465715.
    • (2008) PPAR Res , vol.2008 , pp. 465715
    • Clarke, H.J.1    Gregoire, F.2    Ma, F.3    Martin, R.4    Zhao, S.5    Lavan, B.E.6
  • 54
    • 67649598394 scopus 로고    scopus 로고
    • MBX-102/JNJ39659100, a novel peroxisome proliferator activated receptor-ligand with weak transactivation activity retains full anti-diabetic properties in the absence of side effects
    • Gregoire, F.M.; Zhang, F.; Clarke, H.J.; Gustafson, T.A.; Sears, D.D.; Favelyukis, S.; Lenhard, J.; Rentzeperis, D.; Clemens, L.E.; Mu, Y.; Lavan, B.E. MBX-102/JNJ39659100, a novel peroxisome proliferator activated receptor-ligand with weak transactivation activity retains full anti-diabetic properties in the absence of side effects. Mol. Endocrinol., 2009, 23, 975-988.
    • (2009) Mol. Endocrinol , vol.23 , pp. 975-988
    • Gregoire, F.M.1    Zhang, F.2    Clarke, H.J.3    Gustafson, T.A.4    Sears, D.D.5    Favelyukis, S.6    Lenhard, J.7    Rentzeperis, D.8    Clemens, L.E.9    Mu, Y.10    Lavan, B.E.11
  • 55
    • 33645394377 scopus 로고    scopus 로고
    • Novel partial agonist of peroxisome proliferatoractivated receptor-gamma (PPARgamma) recruits PPARgammacoactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro
    • Burgermeister, E.; Schnoebelen, A.; Flament, A.; Benz, J.; Stihle, M.; Gsell, B. A. novel partial agonist of peroxisome proliferatoractivated receptor-gamma (PPARgamma) recruits PPARgammacoactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol., 2006, 20, 809-830.
    • (2006) Mol. Endocrinol , vol.20 , pp. 809-830
    • Burgermeister, E.1    Schnoebelen, A.2    Flament, A.3    Benz, J.4    Stihle, M.5    Gsell, B.A.6
  • 58
    • 33644858190 scopus 로고    scopus 로고
    • Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma
    • Pershadsingh, H.A. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int. J. Biochem. Cell Biol., 2006, 38, 766-781
    • (2006) Int. J. Biochem. Cell Biol , vol.38 , pp. 766-781
    • Pershadsingh, H.A.1
  • 59
    • 2442451618 scopus 로고    scopus 로고
    • Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
    • Schupp, M.; Janke, J.; Clasen, R.; Unger, T.; Kintscher, U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation, 2004, 109, 2054-2057.
    • (2004) Circulation , vol.109 , pp. 2054-2057
    • Schupp, M.1    Janke, J.2    Clasen, R.3    Unger, T.4    Kintscher, U.5
  • 60
    • 79955032219 scopus 로고    scopus 로고
    • Telmisartan: A review of its use in cardiovascular disease prevention
    • Frampton, J.E. Telmisartan: a review of its use in cardiovascular disease prevention. Drugs, 2011, 71, 651-677.
    • (2011) Drugs , vol.71 , pp. 651-677
    • Frampton, J.E.1
  • 61
    • 11144313062 scopus 로고    scopus 로고
    • Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property
    • Yamagishi, S.; Takeuchi, M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med. Hypotheses, 2005, 64, 476-478.
    • (2005) Med. Hypotheses , vol.64 , pp. 476-478
    • Yamagishi, S.1    Takeuchi, M.2
  • 62
    • 33745982069 scopus 로고    scopus 로고
    • Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in dietinduced obese mice
    • Araki, K.; Masaki, T.; Katsuragi, I.; Tanaka, K.; Kakuma, T.; Yoshimatsu, H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in dietinduced obese mice. Hypertension, 2006, 48, 51-57.
    • (2006) Hypertension , vol.48 , pp. 51-57
    • Araki, K.1    Masaki, T.2    Katsuragi, I.3    Tanaka, K.4    Kakuma, T.5    Yoshimatsu, H.6
  • 63
    • 79953721690 scopus 로고    scopus 로고
    • Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension
    • Bekki, H.; Yamamoto, K.; Sone, M.; Homma, T.; Nakata, M.; Nohara, M.; Fukami, K.; Okuda, S.; Yamagishi, S. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension. Clin. Cardiol., 2011, 34, 261-265.
    • (2011) Clin. Cardiol , vol.34 , pp. 261-265
    • Bekki, H.1    Yamamoto, K.2    Sone, M.3    Homma, T.4    Nakata, M.5    Nohara, M.6    Fukami, K.7    Okuda, S.8    Yamagishi, S.9
  • 64
    • 0033625677 scopus 로고    scopus 로고
    • Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)
    • Peters, J.M.; Lee, S.S.; Li, W.; Ward, J.M.; Gavrilova, O.; Everett, C.; Reitman, M.L.; Hudson, L.D.; Gonzalez, F.J. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol., 2000, 20, 5119-5128.
    • (2000) Mol. Cell. Biol , vol.20 , pp. 5119-5128
    • Peters, J.M.1    Lee, S.S.2    Li, W.3    Ward, J.M.4    Gavrilova, O.5    Everett, C.6    Reitman, M.L.7    Hudson, L.D.8    Gonzalez, F.J.9
  • 66
    • 79955420151 scopus 로고    scopus 로고
    • The Role Played by the Peroxisome Proliferator-Activated Receptor-P///PPARP///Activator, GW501516, in Control of Fatty Acid Metabolism: A New Potential Therapeutic Target for Treating Metabolic Syndrome
    • Lee, J.; Chung, W.Y. The Role Played by the Peroxisome Proliferator-Activated Receptor-P///PPARP///Activator, GW501516, in Control of Fatty Acid Metabolism: A New Potential Therapeutic Target for Treating Metabolic Syndrome. Endocrinology, 2011, 152, 1742-1744.
    • (2011) Endocrinology , vol.152 , pp. 1742-1744
    • Lee, J.1    Chung, W.Y.2
  • 67
    • 13844314826 scopus 로고    scopus 로고
    • Herbal or natural medicines as modulators of peroxisome proliferatoractivated receptors and related nuclear receptors for therapy of metabolic syndrome
    • Huang, T.H.; Kota, B.P.; Razmovski, V.; Roufogalis, B.D. Herbal or natural medicines as modulators of peroxisome proliferatoractivated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin. Pharmacol. Toxicol., 2005, 96, 3-14.
    • (2005) Basic Clin. Pharmacol. Toxicol , vol.96 , pp. 3-14
    • Huang, T.H.1    Kota, B.P.2    Razmovski, V.3    Roufogalis, B.D.4
  • 68
    • 79959536439 scopus 로고    scopus 로고
    • Laboratory studies on weight control and prevention of metabolic syndrome by green tea
    • Sae-Tan, S.; Grove, K.A.; Lambert, J.D. Laboratory studies on weight control and prevention of metabolic syndrome by green tea. Pharmacol. Res., 2011, 64, 146-154.
    • (2011) Pharmacol. Res , vol.64 , pp. 146-154
    • Sae-Tan, S.1    Grove, K.A.2    Lambert, J.D.3
  • 69
    • 45549102505 scopus 로고    scopus 로고
    • Effects of green tea on insulin sensitivity, lipid profile and expression of pparalpha and ppargamma and their target genes in obese dogs
    • Serisier, S.; Leray, V.; Poudroux, W.; Magot, T.; Ouguerram, K.; Nguyen, P. Effects of green tea on insulin sensitivity, lipid profile and expression of pparalpha and ppargamma and their target genes in obese dogs. Br. J. Nutr., 2008, 99, 1208-1216.
    • (2008) Br. J. Nutr , vol.99 , pp. 1208-1216
    • Serisier, S.1    Leray, V.2    Poudroux, W.3    Magot, T.4    Ouguerram, K.5    Nguyen, P.6
  • 70
    • 79951795388 scopus 로고    scopus 로고
    • Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome
    • Tan, Y.; Kamal.; M.A.; Wang, Z.Z.; Xiao, W.; Seale, J.P.; Qu, X. Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. Clin. Sci. (Lond), 2011, 120, 297-305.
    • (2011) Clin. Sci. (Lond) , vol.120 , pp. 297-305
    • Tan, Y.1    Kamal, M.A.2    Wang, Z.Z.3    Xiao, W.4    Seale, J.P.5    Qu, X.6
  • 72
    • 79951808906 scopus 로고    scopus 로고
    • Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice
    • Halade, G.V.; Williams, P.J.; Lindsey, M.L. Fernandes, G. Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacol. Res., 2011, 63, 300-307.
    • (2011) Pharmacol. Res , vol.63 , pp. 300-307
    • Halade, G.V.1    Williams, P.J.2    Lindsey, M.L.3    Fernandes, G.4
  • 73
    • 42449125303 scopus 로고    scopus 로고
    • Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    • Gani, O.A. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists? Cardiovasc. Diabetol., 2008, 20, 7, 6.
    • (2008) Cardiovasc. Diabetol , vol.20
    • Gani, O.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.